B. Yulug Et Al. , "Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial," Translational Neurodegeneration , vol.12, no.1, 2023
Yulug, B. Et Al. 2023. Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial. Translational Neurodegeneration , vol.12, no.1 .
Yulug, B., Altay, O., Li, X., Hanoğlu, L., Cankaya, S., Lam, S., ... Velioglu, H. A.(2023). Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial. Translational Neurodegeneration , vol.12, no.1.
Yulug, Burak Et Al. "Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial," Translational Neurodegeneration , vol.12, no.1, 2023
Yulug, Burak Et Al. "Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial." Translational Neurodegeneration , vol.12, no.1, 2023
Yulug, B. Et Al. (2023) . "Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial." Translational Neurodegeneration , vol.12, no.1.
@article{article, author={Burak Yulug Et Al. }, title={Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial}, journal={Translational Neurodegeneration}, year=2023}